Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 7/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30250301 | 0.90 | CFTR (0.49) | FLT1KDRARCYP3A4SMN1; SMN2 | |
| SCHEMBL2239932 | 0.89 | PDGFRB (0.45) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL16647610 | 0.85 | ALDH1A1 (0.51) | ARSMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL2390749 | 0.84 | CFTR (0.62) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL1301766 | 0.84 | CHEK1 (0.46) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL2247382 | 0.83 | PDGFRB (0.50) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL2895340 | 0.83 | PDGFRB (0.50) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL2035638 | 0.83 | CFTR (0.43) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL2597417 | 0.83 | CFTR (0.43) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL22833807 | 0.83 | CFTR (0.43) | PDGFRBFGFR1PDGFRAFLT1FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4583867-A2 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | Latigo Biotherapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| CN-119894509-A | Sodium channel blocking compounds, derivatives thereof, and methods of use thereof | 拉堤果生物医疗股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-115667241-B | Trka inhibitors | 伊莱利利公司 | 2024-04-16 | — | — | CN | disclosed |
| WO-2024054622-A2 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| EP-4126842-B1 | TRKA INHIBITOR | LILLY CO ELI (US) | 2023-06-28 | — | — | EP | disclosed |
| EP-4126842-B1 | TRKA INHIBITOR | LILLY CO ELI (US) | 2023-06-28 | — | — | EP | disclosed |
| EP-4126842-A1 | TRKA INHIBITOR | ELI LILLY AND COMPANY (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115667241-A | TrkA inhibitors | 伊莱利利公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20210371399-A1 | TrkA Inhibitor | ELI LILLY AND COMPANY | 2021-12-02 | — | — | US | disclosed |
| US-20210371399-A1 | TrkA Inhibitor | ELI LILLY AND COMPANY | 2021-12-02 | — | — | US | disclosed |
| WO-2021242677-A1 | TRKA INHIBITOR | ELI LILLY AND COMPANY (US) | 2021-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371399-A1 | TrkA Inhibitor | NGF, NGFR, OPRL1 | PDGFRB 106/4885FGFR1 215/4885PDGFRA 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.